<DOC>
	<DOCNO>NCT02630108</DOCNO>
	<brief_summary>It prospective multi-center clinical research China compare efficacy , safety related impact factor TACE alone TACE combine synchronous multi-point MWA/RFA large huge liver cancer .</brief_summary>
	<brief_title>TACE Combined With Synchronous Radiofrequency /Microwave Ablation Treat Large Huge Hepatocellular Carcinoma</brief_title>
	<detailed_description>It open random prospective phase III clinical trial conduct Principal Investigator Professor Jian-Hua Wang . Investigators twenty-five hospital China participate . Patients unresectable large HCC ( &gt; 5cm diameter ) huge HCC ( &gt; =10cm diameter ) enrol . The investigator propose recruitment 280 patient randomly assign combined group ( treated TACE synchronous ablation ) control group ( treated TACE alone ) accord proportion 1:1 , mean 140 patient group . The criterion inclusion exclusion , method lab test , image modality treatment procedure .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>1 . Patients primary liver cancer age 1880 year , life expectancy longer three month ; 2 . Patients large HCC ( &gt; 5cm diameter ) huge HCC ( ≥10cm diameter ) , include HCC mixed type liver cancer ( HCCICC ) ; 3 . Patients thrombus main portal vein ( PV ) 4 . Patients ' liver function classify ChildPugh A B , ECOG PS ≤ 2 ; 5 . Patients without bleed tendency coagulation disorder , reversible coagulopathy therapy ; 6 . White blood cell count ≥ 3.0×10^9/L ; 7 . Hemoglobin ≥ 8.5g/dl ; 8 . Platelet ≥ 50×10^9/L ; 9 . INR ≤ 2.3 PT exceed upper limit reference 3 second ; 10 . Blood creatinine less 1.5 time upper limit reference ; 11 . Patients and/or relative willing join clinical trial signing informed consent . 1 . Patients diffuse type liver cancer ; 2 . Cholangiocellular carcinoma 3 . Patients main PV thrombus ; 4 . Patients hepatic vein thrombus ; 5 . Patients lymph node distant metastasis outside liver ; 6 . Patients ' liver function classify ChildPugh C improvement treatment liver protection ; 7 . Patients irreversible coagulation disorder abnormality blood routine test , obvious bleeding tendency ; 8 . Patients intractable massive ascites ; 9 . Patients ' ECOG PS &gt; 2 ; 10 . Patients complicate active infection , especially cholangitis ; 11 . Patients severe disorder heart , lung , kidney , brain ; 12 . Patients and/or relative refuse anticipate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>HCC</keyword>
	<keyword>TACE</keyword>
	<keyword>Thermal Ablation</keyword>
	<keyword>Safety/Efficacy</keyword>
</DOC>